ライフサイエンスコーパス: ductus arteriosus

1 ous lobar pulmonary veins or a silent patent ductus arteriosus.

2 on (PPHN) following prenatal ligation of the ductus arteriosus.

3 ension (PPHN) after prenatal ligation of the ductus arteriosus.

4 rta, suggesting little effect on tone of the ductus arteriosus.

5 neonates without clinically suspected patent ductus arteriosus.

6 predictive value for the presence of patent ductus arteriosus.

7 rteriosus, with a 92% specificity for patent ductus arteriosus.

8 phy (RVH) caused by prolonged closure of the ductus arteriosus.

9 shed techniques for coil occlusion of patent ductus arteriosus.

10 essels, SM2 is precociously expressed in the ductus arteriosus.

11 , we observe a strong beta-gal signal in the ductus arteriosus.

12 ed calcium channels, and constriction of the ductus arteriosus.

13 ribute to the unique muscle phenotype of the ductus arteriosus.

14 shunting following coil occlusion of patent ductus arteriosus.

15 h those of 14 preterm infants without patent ductus arteriosus.

16 e-dimensional image of the great vessels and ductus arteriosus.

17 with intraventricular hemorrhage and patent ductus arteriosus.

18 onary artery stenoses, and persistent patent ductus arteriosus.

19 ath or bronchopulmonary dysplasia and patent ductus arteriosus.

20 d as they may cause premature closure of the ductus arteriosus.

21 atal necrotizing enterocolitis or persistent ductus arteriosus.

22 a Notch ligand, die postnatally from patent ductus arteriosus.

23 the development of smooth muscle within the ductus arteriosus.

24 of indomethacin to treat symptomatic patent ductus arteriosus.

25 all groups, as was acute constriction of the ductus arteriosus.

26 ung disease, there is delayed closure of the ductus arteriosus.

27 nt, despite success in closure of the patent ductus arteriosus.

28 , atrial septal defects (20/47, 43%), patent ductus arteriosus (16/47, 34%), persistent left superior

29 21, 261); superior vena cava, 137 (77, 197); ductus arteriosus, 187 (109, 265); descending aorta, 252

30 4 with atrial septal defects, 2 with patent ductus arteriosus, 2 with tetralogy of Fallot, and 1 wit

31 ransposition of the great vessels, 3 patient ductus arteriosus, 3 partial anomalous pulmonary venous

32 The narrowest diameter of the ductus arteriosus (4.3 +/- 0.4 mm vs. 6.9 +/- 2.6 mm, p

33 1 (29, 53); superior vena cava, 29 (15, 43); ductus arteriosus, 41 (25, 57); descending aorta, 55 (35

34 ngenital heart disease that results when the ductus arteriosus, a muscular artery, fails to remodel a

35 and Cx43 knockout mice an attenuation of the ductus arteriosus, a phenotype which may be indicative o

36 n group than in the placebo group had patent ductus arteriosus (adjusted relative risk, 1.65; 95% CI,

37 PGT plays a critical role in closure of the ductus arteriosus after birth by ensuring a reduction in

38 etal ductus arteriosus and in closure of the ductus arteriosus after birth.

39 normal patterning and differentiation of the ductus arteriosus and adjacent descending aorta.

40 differentiation in the vascular wall of the ductus arteriosus and adjacent descending aorta.

41 In other areas, such as patent ductus arteriosus and atrioventricular septal defect, th

42 banding with catheterization stenting of the ductus arteriosus and balloon atrial septostomy, especia

43 l relationship exists between patency of the ductus arteriosus and chronic lung disease and other mor

44 h epilepsy and other signs, including patent ductus arteriosus and coagulopathy, while hemizygous mal

45 Patent ductus arteriosus and coarctation of aorta occurred >3 t

46 All patients had persistent ductus arteriosus and congenital mydriasis, and variable

47 al valve inflow and direction of flow in the ductus arteriosus and descending aorta were unrelated to

48 599+1delG) was identified in familial patent ductus arteriosus and found to disrupt normal splicing o

49 ole both in maintaining patency of the fetal ductus arteriosus and in closure of the ductus arteriosu

50 riosus to close after birth is termed patent ductus arteriosus and is one of the most common congenit

51 oth muscle differentiation in the developing ductus arteriosus and may promote precocious expression

52 cular interest because it also causes patent ductus arteriosus and moyamoya disease.

53 s describing an association between a patent ductus arteriosus and the development of morbidities, su

54 ending, transverse and descending aorta, the ductus arteriosus, and across the aortic and mitral valv

55 comitant cardiac lesion, for example, patent ductus arteriosus, and aortic cross-clamp time were dete

56 ents with interatrial communications, patent ductus arteriosus, and pulmonary artery stenosis requiri

57 ung age at angioplasty, presence of a patent ductus arteriosus, and the diameters of the aortic isthm

58 Neonatal ductus arteriosus aneurysm (DAA) is a rare abnormality t

59 o [AOR], 0.81; 95% CI, 0.67-0.98) and patent ductus arteriosus (AOR, 0.74; 95% CI, 0.62-0.89).

60 ect (aORs ranging from 1.29 to 2.17), patent ductus arteriosus [aORs = 1.54, 1.63; 95% confidence int

61 Therapies designed to close the ductus arteriosus are contraindicated in some settings a

62 ng the aorta, pulmonary arteries, and patent ductus arteriosus, are each amenable to transcatheter in

63 Much of the normoxic contraction of the ductus arteriosus at birth is related to calcium entry t

64 Closure of the ductus arteriosus at birth, essential for postnatal adap

65 ambs (126+/-3 d; 147 d, term) we ligated the ductus arteriosus at surgery, and treated animals with e

66 on being stenting or stent redilation of the ductus arteriosus, balloon aortic valvuloplasty, and ste

67 onates subsequently diagnosed to have patent ductus arteriosus, based on clinical suspicion and echoc

68 re infants with than in those without patent ductus arteriosus because afterload is lower in the form

69 and atrioventricular septal defects, patent ductus arteriosus, bicuspid aortic valve, and coarctatio

70 ation, P62R, had a high prevalence of patent ductus arteriosus but had only mild abnormalities of fac

71 y intense beta-gal staining localizes to the ductus arteriosus but is absent or minimal in the pulmon

72 are common after coil embolization of patent ductus arteriosus, but most close spontaneously.

73 ght to establish and maintain patency of the ductus arteriosus by a new method of transvascular forma

74 ion of this pathway may contribute to patent ductus arteriosus by affecting the development of smooth

75 nificant role in control of major vessel and ductus arteriosus caliber in the rat fetus.

76 dysmorphology, osteochondrodysplasia, patent ductus arteriosus, cardiomegaly, pericardial effusion, a

77 In the vast majority of infants, the ductus arteriosus closes by 3 days of life.

78 erization of PGHS1-PGHS2 may explain how the ductus arteriosus closes normally at birth in mice expre

79 Incidence of spontaneous ductus arteriosus closure was increased, likely contribu

80 To determine the role of PGT in ductus arteriosus closure, we used a gene-targeting stra

81 ductus arteriosus vessels, VU0542270 induced ductus arteriosus constriction in a dose-dependent manne

82 Neural crest-derived SMCs populating the ductus arteriosus (DA) and great arteries exhibited a ce

83 How the ductus arteriosus (DA) closes at birth remains unclear.

84 Wild-type embryonic ductus arteriosus (DA) exhibited high levels of PRDM6, w

85 The ductus arteriosus (DA) is a vessel whose patency is requ

86 Closure of the ductus arteriosus (DA) is essential for the transition f

87 The ductus arteriosus (DA) of newborn infants exposed in ute

88 Ductus arteriosus (DA) tortuosity was present in signifi

89 as in the fetus, PGs maintain patency of the ductus arteriosus (DA), a vascular shunt that transmits

90 occurs is the closure and remodeling of the ductus arteriosus (DA), an arterial connection in the fe

91 placental mammals depends on closure of the ductus arteriosus (DA), an arterial connection in the fe

92 tic change that occurs is the closure of the ductus arteriosus (DA), an arterial connection in the fe

93 nd neonate, including adverse effects on the ductus arteriosus (DA).

94 Fetal aortic and pulmonary valve; ductus arteriosus (DA); and right (RPA), left (LPA), and

95 ghts into the genetic programs that underlie ductus arteriosus development and closure.

96 y artery diameter Z score <or=-2.5 or patent ductus arteriosus diameter <or=2 mm was 97% sensitive an

97 nly one infant required ligation of a patent ductus arteriosus during ECMO.

98 r morphogenetic development of the aorta and ductus arteriosus during embryonic and postnatal surviva

99 oth muscle layers of the tunica media in the ductus arteriosus exhibit positive beta-gal staining.

100 somal dominant trait characterized by patent ductus arteriosus, facial dysmorphism and hand anomalies

101 ation was observed between PM(10) and patent ductus arteriosus (for an interquartile range increase i

102 001 to 7.5 per mille in 2012-2013, of patent ductus arteriosus from 1.9 per mille to 4.1 per mille, a

103 amicin clearance was decreased in the patent ductus arteriosus group vs. the control group (40.02 vs.

104 nce of a haemodynamically significant patent ductus arteriosus had a significant independent impact o

105 The infants with patent ductus arteriosus had higher values for ventricular perf

106 hough transcatheter coil occlusion of patent ductus arteriosus has gained popularity, few follow-up d

107 r the prevention and treatment of the patent ductus arteriosus have not documented a decrease in the

108 ationale: Hemodynamically significant patent ductus arteriosus (hsPDA) in premature infants has been

109 transcription factor associated with patent ductus arteriosus in humans, was uniquely expressed in m

110 ms underlying O2-induced constriction of the ductus arteriosus in late-gestation fetal rabbits.

111 PRRs of ASD and persistent ductus arteriosus in term infants increased with materna

112 hysiologic flow across the atrial septum and ductus arteriosus in the human fetus.

113 ns (P .05) and with medically managed patent ductus arteriosus in the white matter and deep gray matt

114 Ligation of the ductus arteriosus in utero produces pulmonary hypertensi

115 ) receptor antagonist, after ligation of the ductus arteriosus in utero.

116 in cardiopulmonary defects, including patent ductus arteriosus, in 30 to 40% of the mice.

117 f aortic branch defects, ASD, and persistent ductus arteriosus increase with maternal obesity severit

118 nchopulmonary dysplasia, surgery, and patent ductus arteriosus interventions (all p < 0.01/p < 0.01),

119 dities, including perinatal jaundice, patent ductus arteriosus, intraventricular hemorrhage, perinata

120 the effector mechanism for O2 sensing in the ductus arteriosus involves the coordinated action of del

121 The ductus arteriosus is a specialized blood vessel containi

122 The ductus arteriosus is a vessel that connects the pulmonar

123 The ductus arteriosus is a vital fetal structure allowing bl

124 The ductus arteriosus is an arterial vessel that shunts bloo

125 opment and persists in the neonate until the ductus arteriosus is completely closed.

126 In the preterm newborn, a patent ductus arteriosus is in large part a result of the incre

127 an pulmonary artery pressure (PAP) 8 d after ductus arteriosus ligation (78+/-2, HTN vs. 70+/-4 mmHg,

128 Patent ductus arteriosus ligation among preterm neonates younge

129 Since the first patent ductus arteriosus ligation by Robert Gross of Boston in

130 All 14 premature infants undergoing patent ductus arteriosus ligation in a 1-year period at our ins

131 In preterm infants, patency of the ductus arteriosus may represent a normal physiologic ada

132 istance associated with ligation of a patent ductus arteriosus might worsen ventricular performance i

133 ight represent novel therapeutics for patent ductus arteriosus, migraine headache, and sepsis; howeve

134 rses of gentamicin were administered (patent ductus arteriosus, n = 106; control, n = 216).

135 Patent ductus arteriosus occlusion can be accomplished by umbre

136 ersal of the physiologic shunting across the ductus arteriosus or atrial septum in utero (i.e., left

137 Patients with persistent ductus arteriosus or congenital mydriasis with a label o

138 Impaired development of the ductus arteriosus or disruption of signaling pathways th

139 n with secundum atrial septal defect, patent ductus arteriosus, or pulmonic stenosis have had infecti

140 termine whether the presence and duration of ductus arteriosus patency differs between extremely pret

141 oth the presence of and a longer duration of ductus arteriosus patency were associated with the devel

142 olume of distribution was greater for patent ductus arteriosus patients (0.61 L/kg) than for controls

143 Transcatheter closure of the patent ductus arteriosus (PDA) has increasingly been adopted in

144 of buttoned device (BD) occlusion of patent ductus arteriosus (PDA) in a large number of patients wi

145 us for the screening and treatment of patent ductus arteriosus (PDA) in extremely preterm infants.

146 The management of patent ductus arteriosus (PDA) in preterm infants is controvers

147 ibitor ibuprofen may be used to treat patent ductus arteriosus (PDA) in preterm infants.

148 Nonsyndromic patent ductus arteriosus (PDA) is a common congenital heart def

149 Patent ductus arteriosus (PDA) is a common congenital heart dis

150 t pulmonary vascular development, and patent ductus arteriosus (PDA) is a factor potentially associat

151 Patent ductus arteriosus (PDA) is a relatively common form of c

152 Stenting of the patent ductus arteriosus (PDA) is an established palliative opt

153 Patent ductus arteriosus (PDA) is associated with increased mor

154 Observational studies have associated patent ductus arteriosus (PDA) ligation among preterm infants w

155 old female with a history of neonatal patent ductus arteriosus (PDA) ligation, left-sided choreiform

156 Patent ductus arteriosus (PDA) poses a diagnostic and therapeut

157 rformed to determine the frequency of patent ductus arteriosus (PDA) reopening and the factors that m

158 ated with growth after days 1-8, with patent ductus arteriosus (PDA) showing negative associations wi

159 A patent ductus arteriosus (PDA) shunt may be a modifiable risk f

160 may undergo palliation with either a patent ductus arteriosus (PDA) stent or a modified Blalock-Taus

161 y blood flow, initial palliation with patent ductus arteriosus (PDA) stent or modified Blalock-Taussi

162 theter closure of a moderate to large patent ductus arteriosus (PDA) using conventional techniques is

163 matic echocardiographic screening for patent ductus arteriosus (PDA) vs those who did not undergo scr

164 The patent ductus arteriosus (PDA) was the first congenital heart l

165 ne atrial septal defect (ASD) and two patent ductus arteriosus (PDA) were missed by DSCT.

166 We found that patent ductus arteriosus (PDA), a common congenital heart disea

167 ors are commonly used in infants with patent ductus arteriosus (PDA), but the benefit of these drugs

168 il occlude the moderate to large size patent ductus arteriosus (PDA).

169 eceiving indomethacin (INDO) to close patent ductus arteriosus (PDA).

170 ), coarctation of the aorta (CoA) and patent ductus arteriosus (PDA).

171 neurysmal dilatation of the aorta and patent ductus arteriosus (PDA).

172 ut died prior to postnatal day 3 from patent ductus arteriosus (PDA).

173 locus at 16p for TAAD associated with patent ductus arteriosus (PDA).

174 eptal defect (ASD); device closure of patent ductus arteriosus (PDA); pulmonary valvuloplasty; aortic

175 use of Gianturco coils to close large patent ductus arteriosus (PDAs) (> or = 3.5 mm) and describes t

176 an average difference of 19% +/- 12 between ductus arteriosus plus isthmus flow versus descending ao

177 Maintaining patency of the ductus arteriosus postnatally is necessary with many for

178 and atrioventricular septal defects; patent ductus arteriosus; pulmonary stenosis; aortic stenosis;

179 right and left pulmonary arteries (QP), and ductus arteriosus (QDA) were calculated in 63 normal fet

180 r leukomalacia, chronic lung disease, patent ductus arteriosus requiring surgery, retinopathy of prem

181 nce of a haemodynamically significant patent ductus arteriosus results in a deeper impairment of cere

182 Although a persistent patent ductus arteriosus results in diminished cardiac function

183 s been controversy as to whether or when the ductus arteriosus should be closed by either pharmacolog

184 ts who were delivered alive from the reverse ductus arteriosus shunt group and 4 of 12 from the rever

185 Reversed ductus arteriosus shunting was found with severe right h

186 fetal development, a specialized vessel the ductus arteriosus, shunts blood from the pulmonary arter

187 Medical treatment for patent ductus arteriosus significantly decreased over the study

188 ther modified Blalock-Taussig shunt (BTS) or ductus arteriosus stent (DAS).

189 septal defects, patent foramen ovale, patent ductus arteriosus, stent placement for pulmonary artery

190 sure can result in persistent patency of the ductus arteriosus, the third most common congenital hear

191 increase in oxygen causes contraction of the ductus arteriosus, thus diverting blood flow to the lung

192 Failure of the ductus arteriosus to close after birth is termed patent

193 ng should be altered in neonates with patent ductus arteriosus to reflect the impact of higher volume

194 AOR, 65.24; 95% CI, 5.70-748.18), and patent ductus arteriosus treatment after 72 hours of life vs ea

195 ion, hypoplastic left heart syndrome, patent ductus arteriosus, valvar pulmonary stenosis, tetralogy

196 aging (secundum atrial septal defect, patent ductus arteriosus, ventricular septal defect, pulmonary

197 sure myography experiments on isolated mouse ductus arteriosus vessels, VU0542270 induced ductus arte

198 t transvascular formalin infiltration of the ductus arteriosus wall has been applied successfully to

199 The ductus arteriosus wall was successfully infiltrated and

200 f transvascular formalin infiltration of the ductus arteriosus wall.

201 d cases regardless of whether preterm patent ductus arteriosus was included.

202 ts who required surgical closure of a patent ductus arteriosus was lower in the budesonide group than

203 ficant constriction of the great vessels and ductus arteriosus was observed with L-NIL, whereas both

204 A functionally closed ductus arteriosus was traversed with a specially designe

205 asthma, smoking in the household, and patent ductus arteriosus were predictive of wheezing in the pre

206 rsistent left superior vena cava, and patent ductus arteriosus, were present in 32% of patients.

207 opment of better therapy to close the patent ductus arteriosus, which constitutes approximately 10% o

208 age, including congenital mydriasis, patent ductus arteriosus with ligation, dysautonomia, low blood

209 Necropsy revealed patent ductus arteriosus with normal intimal thickening but dil

210 n was a useful marker for presence of patent ductus arteriosus, with a 92% specificity for patent duc